Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ('GLP-1") strategic update following important industry developments reported both by Pfizer® Inc. and by Eli Lilly and Company®.
Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.
By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug(s).
As previously announced, Lexaria has already demonstrated in human testing, enhanced delivery performance to the world's ONLY existing orally dosed GLP-1 drug: Rybelsus® (semaglutide), owned by Novo Nordisk®.
On April 14, 2025, Pfizer® announced that it would scrap development of danuglipron as a once-daily oral GLP-1 treatment after a patient in a trial experienced a liver injury possibly related to the drug. This was doubly disappointing since, in December 2023, Pfizer® had discontinued a twice-daily trial dose of danuglipron after unwanted side effects derailed an earlier study.
Similarly, Pfizer® experienced earlier setbacks in 2023 with a different GLP-1 drug, lotiglipron, when it too resulted in elevated liver enzymes in patients who took the drug in earlier clinical studies. Development of safe and effective orally-dosed GLP-1 drugs is extremely challenging even for the largest pharmaceutical companies in the world, and Pfizer® and others still need to rise to the challenge of developing effective oral GLP-1 drugs with minimal side effects.
On April 17, 2025, Eli Lilly reported that their experimental, orally-dosed GLP-1 drug (orfoglipron) resulted in lower blood sugar and lower body weight after 40 weeks in a phase 3 clinical trial. As a result of this news, Eli Lilly's market valuation increased by nearly $100 billion in a single day.
Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration ('FDA'), is likely responsible for the dramatic market response to the news.
Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that 13% to 18% of patients receiving the drug experienced nausea; 19% to 26% experienced diarrhea; and 5% to 14% experienced vomiting. Lexaria's experience with other GLP-1 drugs to date in humans, has shown a trend towards reducing these types of side effects.
Side Effects a Known Challenge.
In the studies just reported (above), and in earlier studies, unwanted side effects remain one of the largest challenges still faced by the industry, seemingly without a solution in sight. The results of another study showed that between 47% and 64% of GLP-1 users with type 2 diabetes discontinued use of their GLP-1 drug within 1 or 2 years, respectively. " Gastrointestinal adverse events were linked to the discontinuation rates.'
Obviously, side effects serious enough to persuade patients to discontinue use of an otherwise effective drug, are a major problem for the industry. For companies like Pfizer®, those side effects have been serious enough to stop drug development in its tracks.
As Lexaria reported on August 28, 2024 and January 14, 2025, DehydraTECH-GLP-1 processing has repeatedly shown its propensity to reduce side effects, including but not limited to gastrointestinal adverse events, in both of the major GLP-1 drugs currently available in the world today, being Eli Lilly's tirzepatide, and Novo Nordisk's® semaglutide. One of the only other GLP-1 drugs on the market today, liraglutide, is currently in pilot testing by Lexaria in humans utilizing DehydraTECH processing.
Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology. Our main goal is to attract pharmaceutical companies seeking the benefits of adopting Lexaria's technology for use with their own existing drug products. This first prong of our strategy has been evidenced and validated by the Company's entry in a material transfer agreement with a pharmaceutical company ('PharmaCO') which was announced in September of 2024. Lexaria continues to collaborate with PharmaCO on evaluating DehydraTECH compositions.
As we noted on November 26, 2024, GLP-1 drugs are either approved for use, or are being investigated for use, in all of the following healthcare sectors:
Most recently, the FDA approved Ozempic ® (semaglutide) owned by Novo Nordisk®, to 'reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease ('CKD'). This has the potential to literally be a life-saver for some of the 37 million adults in America struggling with CKD, which, until now, often had NO CURE.
As we noted on November 7, 2024, growth expectations for the GLP-1 industry - prior to the FDA's approval of semaglutide for treatment of CKD - supported a growing consensus that revenue in the GLP-1 drug sector will soon be over $100 billion per year.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Should You Buy Roku Stock After Its Partnership With Amazon?
Roku's recent partnership with Amazon makes the streaming specialist more attractive. Although it still faces some headwinds, Roku's long-term prospects remain bright. The stock doesn't look too expensive at current levels, either. 10 stocks we like better than Roku › On June 16, Roku (NASDAQ: ROKU) announced a partnership with Amazon (NASDAQ: AMZN) that will allow advertisers access to the streaming specialist's ecosystem through Amazon's advertising platform. This agreement represents a significant move forward for Roku. Although the stock has encountered some headwinds over the past year, this new development once again highlights why Roku stock is worth investing in for those focused on the long game. Let's dig deeper into this partnership between Roku and Amazon -- as well as the rest of the former's business -- to understand why. Amazon is a notable player in the connected TV (CTV) market. However, Roku continues to reign supreme -- it holds a leading market share in the U.S. Amazon's size advantage has not allowed it to take over the top spot, and it's now partnering with its longtime rival. Amazon and Roku will combine their respective audiences, comprising 80 million households and more than 80% of CTV accounts in the U.S., and grant advertisers exclusive access to this large ecosystem through Amazon's demand-side ad platform. This is a win for Roku too. Here's why. One significant long-term opportunity for the company is the continued switch from cable to streaming for viewers and advertisers. However, a highly fragmented CTV landscape presented advertisers with several challenges, including difficulties in reaching targeted audiences across various platforms and effectively managing ad frequency. Roku noted in a recent press release: Early tests of this integration have shown significant results. Advertisers using this new solution reached 40% more unique viewers with the same budget and reduced how often the same person saw an ad by nearly 30%, enabling advertisers to benefit from three times more value from their ad spend. In other words, advertisers should get greater returns from the same amount of spending. The deal helps address some pain points they had and helps sell even more companies on the benefits of pouring ad dollars into the kind of platform that Roku offers. It's worth highlighting again that this deal is valuable to every party involved, largely because of Roku's leading CTV ecosystem. It also points to the strength of its network effect. Since the value of Roku's platform only increases as its audience numbers grow, partnerships of this kind could become more common. Roku has encountered some issues in recent years. Its average revenue per user (ARPU) has stalled, while it remains unprofitable. Though the company no longer reports the ARPU metric, management previously attributed poor ARPU growth to the company's expansion efforts in markets outside the U.S., where it is focusing on scale first, rather than monetization. That's the same blueprint it followed in its more mature markets when it sometimes sold its namesake devices at a loss to onboard enough households within its ecosystem. Investors have seen the results of this strategy in the U.S., where Roku already holds a leading market share. This should give investors confidence that it can achieve similar results in other regions. What about the persistent red ink on the bottom line? Investors vastly prefer profitable companies, especially in this uncertain economic and geopolitical environment. But Roku is making strides in this department too. In the company's first quarter, revenue came in at $1.03 billion, up 16% year over year. The company's net loss per share was $0.19, an improvement from the $0.35 per share loss it reported in the prior-year quarter. Roku might not be consistently profitable, but the company is growing its top line at a good clip and making progress on the bottom line. And overall, the company is still in a great position to cash in on the massive long-term shift from cable to streaming. And here's one more thing that makes the stock attractive. Roku's forward price-to-sales ratio is 2.6 as of this writing. In a stock market at all-time highs and valuations reaching unsustainable levels, Roku's modest valuation is especially rare for a growth stock in a leading industry position. For this and all the other reasons, it's worth purchasing the company's shares. Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Roku. The Motley Fool has a disclosure policy. Should You Buy Roku Stock After Its Partnership With Amazon? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
an hour ago
- CNBC
The record-breaking week in the stock market that could have gone very badly
It was another exciting week on Wall Street as the S & P 500 and Nasdaq each closed Friday at new record highs. Incredible as that was, this week could have easily gone another way. Last Saturday, the world learned that the U.S. had entered the Israel-Iran conflict, dropping several massive bunker busters on Fordo, Iran's underground nuclear facility buried under a mountain, and bombing two other sites, Isfahan and Natanz. While fear of further escalation and a prolonged war involving the U.S. was palpable last weekend, the market on Monday shrugged, betting on the notion that the conflict would not result in systemic risk or slow the U.S. economy and hamper corporate earnings much, if at all. As risky as any military action is given the potential to spiral out of control, they tend not to impact the market for long, unless signs appear that it will start impacting growth and inflation. That has not yet happened. We did see energy prices surge in the week before last Saturday's bombings, but they quickly came back down. West Texas Intermediate crude plunged on Monday and Tuesday. While rising modestly in each subsequent session, WTI plunged more than 11% for the week, breaking a three-week winning streak. The stock market took its cues from oil trading, which allowed for the S & P 500 and Nasdaq records and weekly gains of nearly 3.5% and more than 4%, respectively. Monday is the last day of June and Wall Street's second quarter. For the week ... S & P 500 week to date (WTD) up 3.44%; first positive week in three Month to date (MTD) up 4.42%; on pace for its second positive month in a row Quarter to date (QTD) up 10%; on pace for its best quarter since first quarter 2024 Nasdaq WTD up 4.25% MTD up 6%; on pace for its third positive month in a row QTD up 17.2%; best quarter since second quarter 2020 Energy represents a major input cost, often one of the largest, for just about every business in the world, so a sustained increase in energy prices would crunch profit margins or force price hikes in order to preserve them. At the same time, it represents a large unavoidable cost for consumers, whether they're trying to air condition their homes in the summer, heat their homes in the winter, or fill up their cars. Given these high priority needs, elevated energy costs end up cutting into discretionary budgets – meaning activities such as eating out or shopping would get cut back. The quick pairing back of those energy price increases this past week, however, means that analysts don't need to downwardly revise estimates for growth, inflation, or consumer spending – at least not yet. The full impact of President Donald Trump 's tariffs is still unclear, though they will almost certainly lead to higher prices for consumers. While the de-escalation of tensions in the Mideast, and subsequent pullback in energy prices, were certainly the most important factors supporting this week's market action, interest rate expectations were also in focus. Though several voting members of the Federal Reserve's policymaking committee, including Fed Chairman Jerome Powell , threw cold water on comments from Fed Governors Christopher Waller and Michelle Bowman that they were on board with a July rate cut, investors have nonetheless started to price in a higher likelihood that we see three Fed rate cuts by year-end, up from the odds of just two cuts only a week ago. That's according to the CME FedWatch Tool . Another important update that could influence interest rate decisions came Friday, with the release of the May personal income and spending report. Within that report, we find the personal consumption expenditures (PCE) price index, the Fed's preferred measure of inflation. While headline PCE was in line with expectations, up 0.1% month over month and up 2.3% annually, the core rate was a bit hotter than expected, rising 0.2% month over month and 2.7% versus the year-ago period, both one-tenth of a percentage point above expectations. The warmer core reading, which excludes food and energy, is something to watch and cuts against the case for a July rate cut. Digging into the portfolio, we hosted our June Monthly Meeting this week, providing a rundown of all 30 holdings. Jim Cramer highlighted six rallying stocks that members may want to consider booking profits in, and five others that look like buys. We also answered key member questions and touched on all 10 names in our Bullpen, including Cisco Systems, which was added on Monday . The Bullpen is our watch list of stocks that could, under the right circumstances, join the Charitable Trust. During the June meeting, Jim was itching to buy Cisco and Boeing but decided to wait. Sticking with portfolio updates, Nvidia hit new all-time highs this past week as sentiment around artificial intelligence and data center demand continued to improve. Analysts at Loop Capital slapped a $250-per-share price target on the stock, highlighting the hyperscaler purchase intentions over the next few years, the compute intensity of reasoning models, and increased inference demand resulting from AI agent adoption. Already regaining the title of the most valuable U.S. public company at more than $3.8 trillion, Nvidia at $250 represents roughly 60% upside to Friday $157 close and a market cap of more than $6 trillion. Needless to say, Nvidia was our top performer for the week up more than 9.5%. Data center plays — Eaton, GE Vernova, and Broadcom are also expected to benefit from the AI strong demand. On Tuesday, analysts at Morgan Stanley raised their price target on GE Vernova, while analysts at HSBC upgraded Broadcom to a buy from a hold rating. Broadcom, Eaton , and GE Vernova were our next best stocks for the week. Goldman Sachs rounded out the week's top five as financial stocks got some incrementally positive news this week when the Fed, on Wednesday, proposed lowering capital requirements for large U.S banks that were implemented in the years following the 2008 financial crisis. The move would allow banks, including Club holdings Goldman and Wells Fargo , to lend more freely while making it easier for them to buy more U.S. government bonds. Amazon continues to be in the news as investors work to better understand the opportunity the company has in new areas like online grocery shopping, thanks to its massive logistics network and the implications of advancing it through generative AI, robotics and autonomous vehicles. In health care, shares of Eli Lilly advanced this week despite data released Monday on the company's experimental weight-loss drug, bimagrumab, which is designed to help patients preserve muscle mass. It failed to wow investors. Abbott Laboratories , meanwhile, got some positive news Tuesday when Health & Human Services Secretary Robert F. Kennedy Jr. said that his department will encourage the use of wearable health devices. "My vision is every American is wearing a wearable within four years," RFK Jr. said at a House Energy and Commerce Committee meeting . The news may also bode well for devices like the Apple Watch, especially as more health-related sensors are built in. Speaking of Apple , we still believe it is an incredible company with the "greatest product in the world," as Jim put it , referring to the iPhone. However, we think the company would benefit from modifying its capital allocation plans , focusing less on the buyback and more on AI development, be it via internal R & D, paying up for top talent, or acquiring groundbreaking startups. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
2 hours ago
- Yahoo
Hesai Group (HSAI) Soars 19.26% as New Lidar Secures Safety Certification
Hesai Group (NASDAQ:HSAI) is one of the . Hesai Group soared by 19.26 percent on Thursday to end at $23.10 apiece after achieving a new milestone for its ATX Lidar and safety certification portfolio. In a statement, Hesai Group (NASDAQ:HSAI) said that its ATX, a compact, high-resolution, long-range lidar, officially obtained ISO 26262 ASIL B functional safety certification from SGS-TÜV, the world's leading testing, inspection, and certification institution. ATX marked its fourth ISO 26262 accreditation after after Pandar128, QT128, and AT128. With the new certification, Hesai Group (NASDAQ:HSAI) said it now holds the highest number of ISO 26262 certified products in the world. ISO 26262 is a key standard for the functional safety of electrical and electronic (E/E) systems in vehicles. It calls for carefully planned safety measures at every step of the development process—from safety management and concept design, to system, hardware, and software development. Logistics robots filling packages in a warehouse, preparing for delivery. As vehicles become more dependent on E/E systems, ISO plays an important role in ensuring vehicle components adhere to the most stringent safety standards to reduce costly recalls and prevent passenger injuries. While we acknowledge the potential of HSAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
